Imeka

What Imeka does

Imeka is a Canadian brain imaging technology company that develops ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k)-cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with AI to analyze white matter microstructure from standard MRI scans. The platform performs automated segmentation of 33 fiber bundles, generates quantitative reports comparing each subject to age- and sex-matched controls drawn from a proprietary normative database of over 1,440 subjects, and supports longitudinal tracking. ANDI's measurement capabilities include free water imaging for neuroinflammation, myelin integrity assessment, and axonal integrity measurement, enabling detection of pathology in normal-appearing white matter across conditions such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis. The technology runs on standard 1.5T or 3T MRI scanners from any manufacturer with a 5-8 minute acquisition sequence, and produces a fully automated cloud-based report.

Imeka operates two revenue streams: recurring clinical software licensing of ANDI to imaging centers and hospitals as a regulated medical device, and professional services to pharmaceutical companies for neuroimaging biomarker evaluation in clinical trials. ANDI is deployed across imaging centers in 40+ US states, distributed via direct field sales and through an OEM integration with GE Healthcare's BrainWave advanced diffusion processing application. The company markets primarily through medical conferences (RSNA, ASNR), peer-reviewed publications, and educational content, with a sales-led enterprise go-to-market motion targeting clinical imaging centers and pharmaceutical research partners.

Founded in 2011 by researchers from the Sherbrooke Connectivity Imaging Lab (SCIL), including co-founders Maxime Descoteaux (Chief Science Officer) and Pierre-Marc Jodoin, Imeka is headquartered in Sherbrooke, Quebec with a US regional office in Cambridge, Massachusetts. The company received its initial FDA 510(k) clearance for ANDI in July 2023 and an updated clearance for ANDI 2.0, adding brain volumetric analysis, in November 2025. Strategic partners include GE Healthcare (technology integration) and the Alzheimer's Drug Discovery Foundation (Alzheimer's biomarker development investment).

Name

Imeka

Legal name

IMEKA SOLUTIONS INC.

Website

https://imeka.ca

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Imeka develops ANDI, an FDA-cleared AI-powered clinical software that analyzes brain white matter microstructure from MRI scans for diagnosis and monitoring of TBI, Alzheimer's disease, and multiple sclerosis. The platform serves clinical imaging centers across 40+ US states and pharmaceutical research partners.

Ownership category

akta.pro rank

Product category

Neuroimaging Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

Keywords

• Brain imaging software
• White matter analysis
• Neuroimaging biomarkers
• Diffusion tensor imaging
• Clinical MRI software

Headquarters

HQ city

Sherbrooke

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Clinical Software Licensing: ANDI clinical software is provided to imaging centers, hospitals, and clinics as a regulated medical device. Revenue generated through licensing of the FDA-cleared software for clinical use in patient diagnosis and monitoring.
2. Pharmaceutical Research Services: Services to pharmaceutical companies for clinical trials and drug development research, including neuroimaging biomarker evaluation for neurological diseases such as Alzheimer's disease.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Imeka develops and sells ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k) cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with AI to analyze white matter microstructure in the brain from standard MRI scans. The cloud-based, fully automated platform performs segmentation of 33 fiber tracts, provides age- and sex-matched normative comparisons against a 1,440+ subject reference database, and generates comprehensive clinical reports for neurologists, radiologists, and pharmaceutical researchers.

Product overview

Imeka is a brain imaging technology company offering a unified clinical software platform centered on ANDI (Advanced Neuro Diagnostic Imaging). ANDI is an FDA 510(k)-cleared quantitative DTI analysis tool that processes MRI data to assess white matter microstructure. The product portfolio consists of the core ANDI platform, with ANDI 2.0 representing the latest major version that adds brain volumetry (macrostructure analysis) to its existing microstructure analysis capabilities. Both versions are cloud-based, fully automated, and designed for clinical use in neurology practices.

Differentiator

Problem solved

Functional benefit

Products and services

• ANDI (Advanced Neuro Diagnostic Imaging) FDA 510(k)-cleared clinical software that analyzes white matter microstructure using advanced diffusion tensor imaging (DTI). The proprietary, fully automated, and validated quantitative clinical software performs all steps required to create a streamlined report from raw MRI data, including automated segmentation of 33 fiber tracts and comparison to age- and sex-matched normative references. Designed for clinical imaging centers, hospitals, neurology and radiology practices.
• ANDI 2.0 Enhanced version of ANDI that adds brain volumetric analysis (macrostructure) to the existing white matter microstructure (DTI) analysis. Provides a comprehensive one-stop-shop solution for clinicians assessing brain health, with FDA 510(k) clearance.

Quantifiable outcome

• Data can be collected in as little as 5 minutes on a standard MRI machine
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

Partnerships

One partnership is on record.

• GE HealthcarecoreTechnology or Integration · 5 April 2022GE Healthcare integrated Imeka's non-invasive neuroimaging technology into the BrainWave advanced diffusion processing application. This integration allows researchers and clinicians to analyze diffusion MRI signals in the brain in greater detail, advancing precision medicine for brain health.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• RapidAI: RapidAI provides AI-driven imaging analysis across stroke and broader neurovascular conditions via Rapid MRI/CT platforms. Competes with Imeka in the AI neuroimaging category serving hospitals and clinical trial sponsors, albeit with stronger focus on acute stroke.
• SyntheticMR: SyntheticMR offers SyMRI (including SyMRI Diffusion) for quantitative brain tissue analysis and tissue segmentation from a single MRI scan. Comparable as an FDA-cleared quantitative DTI/brain-volumetry tool sold to clinical radiology and pharma research customers.
• Brainomix: Brainomix develops AI-based imaging biomarkers (e.g., e-Stroke suite) for stroke and vascular neurology, deployed across hospitals globally. Comparable as a regulated, imaging-AI clinical software vendor serving neurology practices and stroke centers.
• QMENTA: QMENTA is a cloud-based neuroimaging analysis platform specializing in DTI, white-matter analysis, and multi-site trial imaging management. Closely matches Imeka's cloud-hosted AI diffusion imaging and pharma biomarker services.
• Cortechs.ai: Cortechs.ai (formerly CorTechs Labs) markets NeuroQuant and LesionQuant, FDA-cleared quantitative MRI post-processing tools for brain volumetry and white-matter lesion analysis. Directly comparable to Imeka's ANDI as a regulated quantitative neuro-imaging software sold to imaging centers and used in MS, Alzheimer's, and TBI workflows.
• Blackford Analysis: Blackford Analysis provides an AI platform that curates and routes radiology AI applications, including neuroimaging algorithms, into clinical imaging workflows. Comparable as an enabler/channel partner for quantitative neurology imaging at imaging centers.
• Olea Medical: Olea Medical develops advanced MRI post-processing software (Olea Sphere) for diffusion, perfusion, and functional imaging used in stroke, MS, and oncology. Overlaps with Imeka's diffusion MRI and DTI analytics for neurological disease diagnosis and pharma research.

Emerging players

• Subtle Medical: Subtle Medical develops AI-based image enhancement tools (SubtleMR, SubtleGAD) for faster and higher-quality MRI. Adjacent to Imeka as an AI-for-MRI technology vendor pursuing OEM and clinical channels, with overlap in the pharma-services and clinical-trial imaging ecosystem.

Broad incumbents

• Viz.ai: Viz.ai is a well-funded imaging-AI company initially focused on stroke (Viz LVO) that has expanded into cardiology and other neurovascular workflows. Comparable as a high-growth regulatory-cleared imaging AI vendor targeting hospitals, though operating at larger scale and across more specialties than Imeka.
• Aidoc: Aidoc is a leading broad medical imaging AI platform with FDA-cleared modules across multiple anatomies, sold enterprise-wide to hospitals and imaging networks. Overlaps with Imeka in clinical radiology AI purchasing, but with a portfolio approach rather than white-matter specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ImekaSolutions
• Xx.com/imeka_imaging

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imeka